VivoSeq
Oncology

Clear Cell Renal Cell Carcinoma

11

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Clear Cell Renal Cell Carcinoma is an emerging landscape with 11 programs across 8 companies. The most active players are Arcus Biosciences, PeptiDream Inc., Bristol-Myers Squibb. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arcus Biosciences logo

Arcus Biosciences

2 programs

Phase 1P

PeptiDream Inc.

2 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3C

Cp Cv

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody440%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 77% of 13 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Active, not recruiting2 · 29%
Not yet recruiting1 · 14%
Completed1 · 14%

Clinical Trials

Trial Activity

7 trials

An Open-Label, Multicenter, Phase 1a/1b, Dose Escalation/Dose Expansion Clinical Trial of Theranostic Pair PD-32766D, a 64Cu-Labeled Peptide and PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX in Adult Participants With Relapsed or Refractory Clear Cell Renal Cell Carcinoma Who Have Progressed From or Could Not be Administered Due to Medical Unsuitability or Limited Access to All Standard of Care Therapies
Recruiting·PPeptiDream Inc.·Phase 1·NCT07688187·60 enrolled
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT06661720·1,040 enrolled
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Recruiting·Arcus Biosciences logoArcus Biosciences·Phase 1·NCT05536141·362 enrolled
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03793166·1,175 enrolled
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT01575548·129 enrolled
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
Not yet recruiting·YYonsei University·Phase 2·NCT07691476·48 enrolled
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Completed·National Cancer Institute (NCI)·Phase 3·NCT00326898·1,943 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)